Essen - Deutsche Krebshilfe is funding new joint project on therapy resistance in pancreatic cancer. The head is Jens Siveke from the West German Tumor Center () at the University Hospital Essen.
Pancreatic cancer is one of the cancers with the highest cancer-related mortality. Ductal pancreatic carcinoma, in particular, is difficult to treat because the tumor cells quickly become resistant to available drugs. “Almost every patient develops resistance to chemotherapy in the course of treatment or is resistant at the beginning of therapy,” explained Siveke.
As part of the joint project, the scientists want to identify the mechanisms of chromatin regulation that control the genetic locations of chemotherapy resistance. The aim is also to reprogram the tumor's regulatory pathways in targeted manner so that it becomes vulnerable to drugs and immunotherapies again.
The molecular causes of resistance in pancreatic cancer are to be determined using newly developed in-vitro and in-vivo models and can be examined on tumor samples from clinical studies.
The joint project includes scientists from the University Hospitals in Bochum, Frankfurt, Göttingen, Ulm and Würzburg. It was selected by the German Cancer Aid as part of the “Translational Oncology” funding priority in two-stage selection process as one of four funded projects and is funded over period of three years with total of 1.3 million euros.